Clinical trial
Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and…
NCT00042510 · Cancer Advances Inc., Industry · Completed
Key facts
| NCT number | NCT00042510 |
|---|---|
| Title | Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer |
| Official title | Open-Label,Multicenter Study of G17DT Immunogen in Combination w/ Cisplatin and 5-FU in Subjects w/ Metastatic or Locally Recurrent Gastric or Gastroesophageal Cancer Previously Untreated With Chemotherapy. |
| Lead sponsor | Cancer Advances Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stomach Neoplasms, Esophageal Neoplasms |
| Intervention type | Biological |
| Interventions | Treatment group |
| Enrollment | 103 |
| Start date | Aug 1, 2000 |
| Primary completion | Feb 1, 2003 |
| Completion | Jul 1, 2004 |
| First posted | Aug 1, 2002 |
| Last update posted | Aug 28, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: